Skip to main content

Table 3 Ongoing clinical trials in maintenance or consolidation setting after first line treatment for SCLC

From: Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

Clinical trial ID

Phase

Setting

Regimen

Endpoint

NCT02046733 (STIMULI)

II

LD-SCLC, after C-RT

Nivolumab plus ipilimumab

OS

PFS

NCT03043599

I/II

LD-SCLC, after Cx

Nivolumab plus ipilimumab plus RT

RP2D

PFS

  1. LD-SCLC Limited-stage Disease Small cell lung cancer, C-RT chemo-radiation, OS Overall Survival, PFS Progression Free Survival, Cx Chemotherapy, RT Radiotherapy, RP2D Recommended Phase 2 Dose, ED-SCLC Extensive-stage Disease Small cell lung cancer
Back to article page